STASH trial: SimvaSTatin in Aneurysmal Subarachnoid Haemorrhage

STASH trial - aim of the study

STASH trial is a multi-centre placebo controlled double blinded phase III trial assessing the clinical benefit of SimvaSTatin in Aneurysmal Subarachnoid Haemorrhage (STASH).

We hypothesis that Simvastatin 40 mg treatment given with 96 hours of the ictus over 3 weeks will reduce the incidence and duration of delayed ischaemic deficits following subarachnoid haemorrhage when compared to placebo, leading to improvements in the short and long term clinical course for these patients.